Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Clinical trial NCT05215574 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05215574
Sponsor: NGM Biopharmaceuticals, Inc
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Pancreatic Cancer Breast Cancer Gastric Cancer Non-small Cell Lung Cancer Cervical Cancer Endocervical Cancer Squamous Cell Carcinoma of Head and Neck Bladder Urothelial Cancer Colorectal Carcinoma Esophageal Cancer Ovarian Cancer Renal Cell Carcinoma

Start date: 2022-03-31
Primary completion: 2025-07-01
Enrollment: 130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.